<p>Genfit SA has provided an update on its commercial, clinical, and research activities. The company reported strong commercial sales of Iqirvo® in primary biliary cholangitis (PBC), with continued updates expected from Ipsen, its commercialization partner. Genfit highlighted progress on its investigational candidate G1090N for acute-on-chronic liver failure (ACLF), noting its safety profile and anti-inflammatory activity and plans to advance into Phase 2 proof-of-concept studies. The company’s oncology program, GNS561 for cholangiocarcinoma (CCA), has demonstrated a favorable safety profile and early antitumor activity, with Phase 2 trials anticipated to begin in the second half of 2026. Additional programs in ACLF and UCD/OA are progressing through preclinical and early clinical stages. Genfit reported a cash position of €119 million at the end of Q3 2025 and projects a cash runway extending beyond 2028. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

GNFT

Genfit SA Highlights Pipeline Progress and Commercial Success in Latest Corporate Presentation